Alexandria Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | $904K | Sell |
8,381
-8
| -0.1% | -$914 | 0.08% | 151 |
|
|
2021
Q2 | $945K | Buy |
8,389
+112
| +1% | +$12.6K | 0.09% | 148 |
|
|
2021
Q1 | $896K | Sell |
8,277
-274
| -3% | -$29.3K | 0.09% | 149 |
|
|
2020
Q4 | $916K | Buy |
8,551
+808
| +10% | +$77.6K | 0.1% | 148 |
|
|
2020
Q3 | $643K | Sell |
7,743
-6
| -0.1% | -$565 | 0.08% | 164 |
|
|
2020
Q2 | $761K | Buy |
7,749
+768
| +11% | +$67.6K | 0.1% | 146 |
|
|
2020
Q1 | $532K | Sell |
6,981
-93
| -1% | -$7.92K | 0.09% | 157 |
|
|
2019
Q4 | $626K | Buy |
7,074
+5
| +0.1% | +$415 | 0.08% | 160 |
|
|
2019
Q3 | $535K | Sell |
7,069
-142
| -2% | -$9.73K | 0.08% | 165 |
|
|
2019
Q2 | $524K | Sell |
7,211
-750
| -9% | -$59K | 0.07% | 180 |
|
|
2019
Q1 | $642K | Sell |
7,961
-50
| -0.6% | -$4.09K | 0.09% | 161 |
|
|
2018
Q4 | $739K | Buy |
8,011
+712
| +10% | +$62.6K | 0.12% | 152 |
|
|
2018
Q3 | $690K | Sell |
7,299
-25
| -0.3% | -$2.37K | 0.1% | 150 |
|
|
2018
Q2 | $679K | Sell |
7,324
-195
| -3% | -$19K | 0.1% | 155 |
|
|
2018
Q1 | $712K | Sell |
7,519
-55
| -0.7% | -$6.04K | 0.11% | 150 |
|
|
2017
Q4 | $733K | Buy |
7,574
+2,850
| +60% | +$269K | 0.11% | 152 |
|
|
2017
Q3 | $420K | Hold |
4,724
| – | – | 0.11% | 105 |
|
|
2017
Q2 | $343K | Hold |
4,724
| – | – | 0.09% | 112 |
|
|
2017
Q1 | $308K | Buy |
4,724
+57
| +1% | +$3.58K | 0.08% | 115 |
|
|
2016
Q4 | $292K | Sell |
4,667
-867
| -16% | -$52.9K | 0.07% | 113 |
|
|
2016
Q3 | $349K | Buy |
5,534
+991
| +22% | +$64.2K | 0.06% | 111 |
|
|
2016
Q2 | $281K | Buy |
4,543
+14
| +0.3% | +$853 | 0.05% | 126 |
|
|
2016
Q1 | $259K | Buy |
4,529
+16
| +0.4% | +$892 | 0.05% | 131 |
|
|
2015
Q4 | $267K | Buy |
4,513
+1,412
| +46% | +$81.3K | 0.07% | 127 |
|
|
2015
Q3 | $169K | Buy |
3,101
+11
| +0.4% | +$716 | 0.04% | 147 |
|
|
2015
Q2 | $208K | Buy |
3,090
+11
| +0.4% | +$718 | 0.05% | 140 |
|
|
2015
Q1 | $180K | Buy |
3,079
+12
| +0.4% | +$725 | 0.06% | 107 |
|
|
2014
Q4 | $201K | Buy |
3,067
+9
| +0.3% | +$567 | 0.08% | 106 |
|
|
2014
Q3 | $177K | Buy |
3,058
+11
| +0.4% | +$611 | 0.08% | 112 |
|
|
2014
Q2 | $172K | Buy |
3,047
+12
| +0.4% | +$630 | 0.07% | 113 |
|
|
2014
Q1 | $156K | Buy |
3,035
+11
| +0.4% | +$556 | 0.07% | 116 |
|
|
2013
Q4 | $160K | Buy |
3,024
+576
| +24% | +$28.3K | 0.07% | 114 |
|
|
2013
Q3 | $110K | Buy |
2,448
+13
| +0.5% | +$576 | 0.05% | 136 |
|
|
2013
Q2 | $101K | Buy |
+2,435
| New | +$106K | 0.05% | 145 |
|
Other funds holding ABBV
Alexandria Capital's ABBV Position: Q3 2021 in Review
Alexandria Capital reduced its AbbVie (ABBV) stake by 0.1% in Q3 2021, selling an estimated $914 and leaving 8,381 shares worth $904K. The position accounts for 0.08% of the portfolio, ranked #151.
Alexandria Capital first reported a position in ABBV in Q2 2013 and has held it in 34 quarters since. The position peaked at $945K in Q2 2021. 2,655 funds tracked by Wall St. Rank hold ABBV as of Q3 2021.
- Alexandria Capital held 8,381 shares of AbbVie worth $904K as of Q3 2021.
- Alexandria Capital sold 8 AbbVie shares in Q3 2021, an estimated $914.
- AbbVie made up 0.08% of Alexandria Capital's portfolio in Q3 2021, its #151 holding.
- Alexandria Capital first reported a position in AbbVie in Q2 2013 and has held it in 34 quarters since.
- Alexandria Capital's AbbVie position peaked at $945K in Q2 2021.
- 2,655 funds tracked by Wall St. Rank held AbbVie as of Q3 2021.
Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.